Johan Skog, PhD, presented “Current State of Exosome-Based Biomarkers” for the Grand Rounds in Urology audience in September, 2019.
How to cite: Skog, Johan. “Current State of Exosome-Based Biomarkers” September, 2019. Accessed Nov 2024. https://dev.grandroundsinurology.com/current-state-of-exosome-based-biomarkers/
Current State of Exosome-Based Biomarkers – Summary:
Johan Skog, PhD, explains how the biology of exosomes and their role in tumor cell growth, angiogenesis, and inhibiting immune cells enables a potential for the use of exosome-based biomarkers in evaluating prostate cancer. He describes evaluating the RNA content of exosomes to provide a more specific analysis of individual patient disease and possibly prevent overdiagnosis and overtreatment of prostate cancer, as well as the ExoDx Prostate(Intelliscore), or EPI, which analyzes urine samples and aims to avoid unnecessary biopsies.
ABOUT THE AUTHOR
Johan Skog, PhD, is a founding scientist and the Chief Scientific Officer of Exosome Diagnostics, a biotechnology company based in Waltham, Massachusetts. Dr. Skog completed his PhD at Umeå University in Sweden, and then moved to Boston, where he served as junior faculty at Massachusetts General Hospital (MGH)/Harvard Medical School and studied RNA profiles in tumor stem cells. Dr. Skog has written extensively on the subject of exosome science and is widely respected for his pioneering work in that field. Notably, he was published in Nature Cell Biology for his discovery that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids. He also showed that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. At Exosome Diagnostics, Dr. Skog continues to expand the field of exosome biology and work on advancements in diagnostics.
